Medicis Pharmaceutical Requests That Inamed Corporation Recommend Rejection Of Allergan Inc. Exchange Offer

SCOTTSDALE, Ariz.--(BUSINESS WIRE)--Nov. 22, 2005--Medicis (NYSE:MRX) today announced that it has formally given notice to Inamed Corporation's (NASDAQ:IMDC) board of directors requesting it recommend to Inamed stockholders that they reject Allergan Inc.'s (NYSE:AGN) exchange offer. Allergan's publicly announced offer is to exchange all outstanding shares of Inamed for either $84 in cash or 0.8498 of a share of Allergan common stock.

Back to news